source
- FDA approves Lipfendra, first oral PCSK9 inhibitor, to lower LDL cholesterol in adultsThe U.S. Food and Drug Administration has approved Lipfendra (enlicitide), the first oral inhibitor of the PCSK9 protein, for use as an adjunct to diet and exercise in adults with high cholesterol,…
- BlossomHill and Latigo lead a surge of biotech IPOs after summer dry spellAfter a seven‑month lull that left no biotech companies on the public markets last summer, the sector is seeing renewed activity. BlossomHill Therapeutics and Latigo have filed to list on Nasdaq,…